Safety Study of PLX4032 in Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Malignant Melanoma, Colorectal Carcinoma

In brief

The primary objective of this FIH study is to assess the safety and pharmacokinetics of PLX4032 in patients with solid tumors. The secondary objective is to assess the pharmacodynamic activity in paired biopsy specimens obtained from patients with malignant melanoma who have the V600E BRAF oncogenic mutation.

Key facts

Study ID

NCT00405587

Run by

Plexxikon

People needed

109

Starts

2006-11-01

Expected to finish

2016-02-01

Last updated by the study team

2017-08-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Solid tumors confirmed histologically whose tumors are refractory to standard therapy, or for whom standard or curative therapy does not exist
• Patients from whom paired melanoma biopsies are planned must have a V600E+ BRAF mutation confirmed prior to the administration of PLX4032
• Previous chemotherapy, immunotherapy, or radiation therapy must have been completed at least 2 weeks prior to starting PLX4032 therapy, and all associated toxicity must be resolved prior to administration of PLX4032
• Patients in the Extension cohorts (melanoma or adenocarcinoma of the colon or rectum) must have both a V600E+ BRAF mutation and measurable disease (by RECIST V 1.0 criteria) prior to the administration of PLX4032. All patients enrolled must provide archival or fresh melanoma tumor biopsy for confirmation of V600E+ BRAF mutation status by TaqMan assay
• ECOG performance status 0 or 1
• Life expectancy ≥ 3 months
• Adequate hematologic, hepatic, and renal function

You may not qualify if…

• Brain metastases that are progressing or have been documented to be stable for less than 3 months, or for which systemic corticosteroids are required
• Investigational drug use within 28 days of the first dose of PLX4032
• Uncontrolled intercurrent illness
• Refractory nausea and vomiting, malabsorption, or significant bowel resection that would preclude adequate absorption

Where it is running

• University of California Los Angeles — Los Angeles, California, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Vanderbilt Ingram Cancer Center — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Peter MacCallum Cancer Centre — East Melbourne, Victoria, Australia
• Royal Melbourne Hospital — Parkville, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.